Clinical contextualization and the assessment of adverse events in HBOC trials

Artificial Cells, Blood Substitutes, and Biotechnology

Volumn 36, Issue 6, 2008, Pages 477-486

  Greenburg, A G ^a   Pitman, A ^a   Pearce, B ^a   Kim, H W ^a  

^a Biopure Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE EVENTS; ALTERNATIVE HYPOTHESIS; CLINICAL TRIALS; CONTEXTUALIZATION; MITIGATION STRATEGIES; OXYGEN CARRIERS; PATHOLOGICAL PROCESSES; PATIENT MANAGEMENTS; PROTOCOL DESIGNS;

OXYGEN;

HEMOGLOBIN; OXYGEN;

CLINICAL ASSESSMENT; CLINICAL PRACTICE; COLLOID; COMORBIDITY; CRYSTALLOID; ERYTHROCYTE CONCENTRATE; HEALTH CARE PERSONNEL; HUMAN; PATIENT CARE; PATIENT EDUCATION; REVIEW; RISK FACTOR;

BLOOD SUBSTITUTES; CLINICAL PROTOCOLS; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HEMOGLOBINS; HUMANS; SAFETY; TREATMENT OUTCOME;

EID: 58149084874     PISSN: 10731199     EISSN: 15324184     Source Type: Journal    
DOI: 10.1080/10731190802554000     Document Type: Review

References (0)